Literature DB >> 18057963

Tumor development in three patients with Noonan syndrome.

Helen Fryssira1, George Leventopoulos, Stavroula Psoni, Sophia Kitsiou-Tzeli, Nikolaos Stavrianeas, Emmanuel Kanavakis.   

Abstract

The diagnosis of Noonan syndrome is essentially clinical, based upon the distinct phenotype and the involvement of the cardiovascular system. Tumor development is a rare manifestation of Noonan syndrome but can be explained by the molecular pathophysiology involved in the disorder. We present three Noonan patients who developed solid tumors. The first patient, a 4-year-old girl, developed granular cell tumors as did her mother in childhood. The second patient, a 1-year-old boy, had a low grade pilocytic astrocytoma, the clinical expression of which was persistent headache. MRI showed a pituitary mass in the posterior lobe. It was surgically removed. The third patient, a 7-year-old boy was found to have Sertoli tumors in his right cryptorchid testis. All three patients fulfilled the clinical criteria for Noonan syndrome. However, genetic testing was negative in patients 1 and 3. The diagnosis of Noonan syndrome was made based on distinct phenotypic findings in three patients who had different types of tumors.

Entities:  

Mesh:

Year:  2007        PMID: 18057963     DOI: 10.1007/s00431-007-0636-3

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  40 in total

1.  Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes.

Authors:  A Sarkozy; E Conti; D Seripa; M C Digilio; N Grifone; C Tandoi; V M Fazio; V Di Ciommo; B Marino; A Pizzuti; B Dallapiccola
Journal:  J Med Genet       Date:  2003-09       Impact factor: 6.318

2.  The role of glial fibrillary acidic protein in the diagnosis of central nervous system tumors.

Authors:  J H Deck; L F Eng; J Bigbee; S M Woodcock
Journal:  Acta Neuropathol       Date:  1978-06-30       Impact factor: 17.088

3.  The Ullrich-Noonan syndrome (Turner phenotype).

Authors:  J J Nora; A H Nora; A K Sinha; R D Spangler; H A Lubs
Journal:  Am J Dis Child       Date:  1974-01

Review 4.  Pitfalls in the diagnosis of brain tumours.

Authors:  Antonio Mp Omuro; Claudia C Leite; Karima Mokhtari; Jean-Yves Delattre
Journal:  Lancet Neurol       Date:  2006-11       Impact factor: 44.182

5.  Noonan syndrome and neuroblastoma.

Authors:  J L Cotton; R G Williams
Journal:  Arch Pediatr Adolesc Med       Date:  1995-11

6.  Clinical and molecular studies in a large Dutch family with Noonan syndrome.

Authors:  I van der Burgt; E Berends; E Lommen; S van Beersum; B Hamel; E Mariman
Journal:  Am J Med Genet       Date:  1994-11-01

7.  Rhabdomyosarcoma in a patient with Noonan syndrome phenotype and review of the literature.

Authors:  Maria Moschovi; Vassiliki Touliatou; Touliatou Vassiliki; Anna Papadopoulou; Papadopoulou Anna; Maria-Alexandra Mayakou; Mayakou Maria-Alexandra; Polyxeni Nikolaidou-Karpathiou; Nikolaidou-Karpathiou Polyxeni; Sophia Kitsiou-Tzeli; Kitsiou-Tzeli Sophia
Journal:  J Pediatr Hematol Oncol       Date:  2007-05       Impact factor: 1.289

8.  Clinical behavior and a contemporary management algorithm for prepubertal testis tumors: a summary of the Prepubertal Testis Tumor Registry.

Authors:  Jonathan H Ross; Lisa Rybicki; Robert Kay
Journal:  J Urol       Date:  2002-10       Impact factor: 7.450

9.  Germline KRAS mutations cause Noonan syndrome.

Authors:  Suzanne Schubbert; Martin Zenker; Sara L Rowe; Silke Böll; Cornelia Klein; Gideon Bollag; Ineke van der Burgt; Luciana Musante; Vera Kalscheuer; Lars-Erik Wehner; Hoa Nguyen; Brian West; Kam Y J Zhang; Erik Sistermans; Anita Rauch; Charlotte M Niemeyer; Kevin Shannon; Christian P Kratz
Journal:  Nat Genet       Date:  2006-02-12       Impact factor: 38.330

10.  Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.

Authors:  Marco Tartaglia; Simone Martinelli; Giovanni Cazzaniga; Viviana Cordeddu; Ivano Iavarone; Monica Spinelli; Chiara Palmi; Claudio Carta; Andrea Pession; Maurizio Aricò; Giuseppe Masera; Giuseppe Basso; Mariella Sorcini; Bruce D Gelb; Andrea Biondi
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

View more
  14 in total

1.  Phenotypic spectrum of 80 Greek patients referred as Noonan syndrome and PTPN11 mutation analysis: the value of initial clinical assessment.

Authors:  Anna Papadopoulou; Michalis Issakidis; Evangelia Gole; Konstantina Kosma; Helen Fryssira; Andreas Fretzayas; Polyxeni Nicolaidou; Sophia Kitsiou-Tzeli
Journal:  Eur J Pediatr       Date:  2011-05-18       Impact factor: 3.183

Review 2.  Germline genetic landscape of pediatric central nervous system tumors.

Authors:  Ivo S Muskens; Chenan Zhang; Adam J de Smith; Jaclyn A Biegel; Kyle M Walsh; Joseph L Wiemels
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

Review 3.  The molecular biology of WHO grade I astrocytomas.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

Review 4.  Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature.

Authors:  Fu-Sung Lo; Ju-Li Lin; Min-Tzu Kuo; Pao-Chin Chiu; San-Ging Shu; Mei-Chyn Chao; Yann-Jinn Lee; Shuan-Pei Lin
Journal:  Eur J Pediatr       Date:  2008-10-29       Impact factor: 3.183

Review 5.  Pathological and molecular advances in pediatric low-grade astrocytoma.

Authors:  Fausto J Rodriguez; Kah Suan Lim; Daniel Bowers; Charles G Eberhart
Journal:  Annu Rev Pathol       Date:  2012-10-29       Impact factor: 23.472

6.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.

Authors:  David T W Jones; Barbara Hutter; Natalie Jäger; Andrey Korshunov; Marcel Kool; Hans-Jörg Warnatz; Thomas Zichner; Sally R Lambert; Marina Ryzhova; Dong Anh Khuong Quang; Adam M Fontebasso; Adrian M Stütz; Sonja Hutter; Marc Zuckermann; Dominik Sturm; Jan Gronych; Bärbel Lasitschka; Sabine Schmidt; Huriye Seker-Cin; Hendrik Witt; Marc Sultan; Meryem Ralser; Paul A Northcott; Volker Hovestadt; Sebastian Bender; Elke Pfaff; Sebastian Stark; Damien Faury; Jeremy Schwartzentruber; Jacek Majewski; Ursula D Weber; Marc Zapatka; Benjamin Raeder; Matthias Schlesner; Catherine L Worth; Cynthia C Bartholomae; Christof von Kalle; Charles D Imbusch; Sylwester Radomski; Chris Lawerenz; Peter van Sluis; Jan Koster; Richard Volckmann; Rogier Versteeg; Hans Lehrach; Camelia Monoranu; Beate Winkler; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Martin Ebinger; Martin U Schuhmann; Yoon-Jae Cho; Scott L Pomeroy; Andreas von Deimling; Olaf Witt; Michael D Taylor; Stephan Wolf; Matthias A Karajannis; Charles G Eberhart; Wolfram Scheurlen; Martin Hasselblatt; Keith L Ligon; Mark W Kieran; Jan O Korbel; Marie-Laure Yaspo; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; V Peter Collins; Nada Jabado; Roland Eils; Peter Lichter; Stefan M Pfister
Journal:  Nat Genet       Date:  2013-06-30       Impact factor: 38.330

Review 7.  MAPK pathway activation in pilocytic astrocytoma.

Authors:  David T W Jones; Jan Gronych; Peter Lichter; Olaf Witt; Stefan M Pfister
Journal:  Cell Mol Life Sci       Date:  2011-12-13       Impact factor: 9.261

Review 8.  Rosette forming glioneuronal tumor in association with Noonan syndrome: pathobiological implications.

Authors:  M Karafin; G I Jallo; M Ayars; C G Eberhart; F J Rodriguez
Journal:  Clin Neuropathol       Date:  2011 Nov-Dec       Impact factor: 1.368

9.  Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation.

Authors:  Marjolijn C J Jongmans; Ineke van der Burgt; Peter M Hoogerbrugge; Kees Noordam; Helger G Yntema; Willy M Nillesen; Roland P Kuiper; Marjolijn J L Ligtenberg; Ad Geurts van Kessel; J Han J M van Krieken; Lambertus A L M Kiemeney; Nicoline Hoogerbrugge
Journal:  Eur J Hum Genet       Date:  2011-03-16       Impact factor: 4.246

Review 10.  Noonan syndrome.

Authors:  Amy E Roberts; Judith E Allanson; Marco Tartaglia; Bruce D Gelb
Journal:  Lancet       Date:  2013-01-10       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.